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Summary. Allogeneic stem cell transplantation from an
HLA-identical sibling donor is a curative treatment option
for a young patient with myelodysplastic syndrome, limited
by age and lack of sibling donors. Alternative stem cell
sources have been used more recently, such as unrelated
donors, non-identical family members or autologous trans-
plants. This analysis of 1378 transplants reported to the
European Group for Blood and Marrow Transplantation
(EBMT) addresses the outcome of the varying procedures
according to the known risk factors. The estimated disease-
free survival (DFS) and estimated relapse risk at 3 years
were both 36% for 885 patients transplanted with stem cells
from matched siblings. In the multivariate analysis, age and
stage of disease had independent prognostic significance for
DFS, survival and treatment-related mortality. Patients
transplanted at an early stage of disease had a significantly
lower risk of relapse than patients transplanted at more
advanced stages. The estimated DFS at 3 years was 25% for
the 198 patients with voluntary unrelated donors, 28% for the
91 patients with alternative family donors and 33% for the
126 patients autografted in first complete remission. The non-
relapse mortality was 58% for patients with unrelated donors,
66% for patients with non-identical family donors and 25% for
autografted patients. The relapse rate of 18% was relatively
low for patients with non-identical family donors, 41% for
patients with unrelated donors and 55% for patients treated
with autologous stem cell transplantation. Both allogeneic and
autologous stem cell transplantation have emerged as treat-
ment options for patients with myelodysplastic syndromes.
Transplantation with an HLA-identical sibling donor is the
preferred treatment option. Patients without an HLA-identical
sibling donor may be treated with either autologous stem cell
transplantation or an alternative donor transplantation.
Patients younger than 20 years may be treated with an
unrelated donor transplantation. Patients older than
40 years, and probably also patients between 20 and
40 years, may benefit most from an autologous stem cell
transplantation.
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The prognosis of the myelodysplastic syndromes (MDS)
varies from a few months to many years. Refractory
anaemia (RA) and RA with ring sideroblasts (RARS) are
characterized by a low risk of transformation to acute
myeloid leukaemia (AML) and a median survival usually in
excess of 30 months (Mufti et al, 1985). In contrast, the
median survival of patients with refractory anaemia and
excess of blasts (RAEB) or RAEB in transformation (RAEBt)
is less than 12 months (Bennett et al, 1982; Kantarjian et al,
1986). The karyotype is an additional prognostic factor for
survival in MDS (Yunis et al, 1986; Geddes et al, 1990; de
Witte et al, 1990a). A recent international workshop has
proposed a scoring system based on cytogenetic abnormal-
ities, marrow blasts and peripheral blood cytopenias, which
identifies patients in whom median survival is , 1 years
(Greenberg et al, 1997).
In view of the lack of curative therapies, allogeneic bone
marrow transplantation (BMT) is the treatment of choice for
young patients with histocompatible siblings. The first cases
were transplanted more than 10 years ago (Appelbaum et al,
1984; de Witte et al, 1984). Subsequent publications have
addressed the role of allogeneic transplantation for MDS
in adults (Appelbaum et al, 1990; Anderson et al, 1993;
O'Donnell et al, 1995) and children (Guinan et al, 1989;
Locatelli et al, 1997). National and international bone
marrow transplant registries have collected data on patients
transplanted for myelodysplasia (de Witte et al, 1990b).
Results of allogeneic BMT depend on the same risk factors as
defined for conventional treatment, such as the presence of
cytogenetic abnormalities (De Witte et al, 1991; Sutton et al,
1996), age (de Witte et al, 1991; Sutton et al, 1996) and the
percentage of blasts in the bone marrow (Anderson et al,
1993; O'Donnell et al, 1995; Sutton et al, 1996). Recently,
donors other than HLA-identical siblings and autologous
cells have been used as alternative sources of stem cells.
This report describes an analysis of the data from 1378
patients transplanted for MDS or secondary acute myeloid
leukaemia (MDS-AML). We focused on prognostic factors,
such as source of transplant (matched sibling vs. mis-
matched family donor or voluntary unrelated donor and
autologous transplant), age of recipient, duration of disease
before BMT conditioning, primary vs. therapy-related MDS
and stage of disease.
PATIENTS AND METHODS
All consecutively reported transplants from 1983 to 1998
were included in this analysis. If a patient received a second
transplant for transplant failure or relapse, then the data
from the second transplant were analysed combined with
those from the first procedure. For example, a patient who
died because of complications after the second transplant for
treatment of relapse was defined as treatment failure due to
relapse. A patient who died because of complications after
the second transplant performed for treatment of rejection
was defined as treatment failure due to treatment-related
complications. Patients with myeloproliferative syndromes
and secondary acute lymphoblastic leukaemia were
excluded from this analysis. Patients who developed MDS
or AML after autologous stem cell transplantation were also
excluded from this analysis.
The data from the 10 patients transplanted for chronic
myelomonocytic leukaemia (CMMoL) and from the 22
patients with unclassifiable MDS were not analysed
separately in view of the low numbers.
All EBMT transplant centres have committed themselves
to report the minimal essential data (Med-A forms) of all
consecutive transplants at the time of the transplantation.
Updates of the data on the Med-A forms have been
performed on a regular basis. The follow-up of the patients
ends at the time of death or the last reported date of being
alive. An increasing number of national registries report all
transplants within the respective country to the megafile of
the EBMT. The EBMT commenced a centre review process in
1996, in which individual teams are audited for the quality
of their data returns.
The present analysis focused on the four main end-points:
disease-free survival, overall survival, relapse incidence and
transplant-related mortality. The analysis concentrated on
well-recognized risk factors, i.e. age of recipient, primary vs.
therapy-related MDS, disease stage at transplantation, time
from diagnosis to transplant and year of transplantation.
Complete cytogenetic data have been reported for a small
minority of patients. Therefore, cytogenetic characteristics
had to be excluded from this analysis.
Definitions. The classification of MDS and acute myeloid
leukaemia (AML) was performed according to the criteria of
the French±American±British (FAB) working group (Ben-
nett et al, 1982). AML that developed after pre-existing
myelodysplasia with a duration of at least 3 months was
defined as secondary acute myeloid leukaemia (MDS-AML).
MDS without a previous history of other haematological
conditions, such as aplastic anaemia, or MDS without a
history of exposure to cytotoxic or immunosuppressive
therapy for malignancies, autoimmune diseases or organ
transplantation were defined as primary MDS.
MDS/AML occurring after other haematological condi-
tions such as aplastic anaemia or MDS/AML occurring after
exposure to cytotoxic or immunosuppressive therapy for
malignancies, autoimmune diseases or organ transplanta-
tion were defined as therapy-related MDS/AML (tMDS/
AML). Patients with blast crisis evolving from myeloproli-
ferative disorders have been excluded from this analysis.
The early stage of MDS was defined as untreated RA/
RARS or MDS in first complete remission (CR-1); inter-
mediate stage as untreated RAEB(t) or MDS in second
complete remission (CR-2); advanced stage as remaining
MDS.
Treatment-related mortality (TRM) or non-relapse mor-
tality was defined as mortality after stem cell transplantation
not occurring after relapse.
Statistics. The time intervals for survival, disease-free
survival, relapse rate and risk of transplant-related mortality
were calculated from the day of stem cell transplantation.
Relapsed patients were censored for transplant-related
mortality from time of relapse. Actuarial curves were
calculated according to the Kaplan±Meier technique (Peto,
1984). The differences between curves were tested statistically
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using the two-tailed log-rank test (Breslow). For ordered
variables, the log-rank test for linear trend was used
(Breslow, 1984). The prognostic value of covariables was
studied by Cox's regression.
RESULTS
Transplantation activity for MDS in Europe
A total of 193 European teams had reported data from
1378 patients by 15 December 1997. Surveys of transplant
activity in Europe indicated that 142 and 216 procedures
were performed in 1992 and 1994 (Gratwohl & Hermans,
1994; Gratwohl et al, 1996). Approximately 150 trans-
plants were reported annually to the EBMT registry from
1992 to 1994, thus confirming that data were available
from more than 90% of all transplants for MDS performed in
Europe. The reported number of transplants for patients
with MDS doubled in the period 1992±94 compared with
the period 1989±92. Transplantation for MDS using
unrelated donors has occurred more recently and has
surpassed transplantation with mismatched family members.
In the period 1992±94, 25 transplants were performed
using non-identical family donors and 82 transplants with
unrelated donors. Only 15 autologous stem cell transplan-
tations (ASCTs) were performed before 1989, but this
application has acquired more acceptance recently. The
number of reported ASCTs for patients with MDS was 64 in
the period 1992±94. Since 1994, more autologous
transplants have been performed with mobilized peripheral
stem cells than with those from marrow.
Transplantation with histocompatible siblings
The most frequent form of transplantation for MDS was
transplantation with stem cells from HLA-identical siblings.
A total of 885 patients were transplanted with matched
sibling stem cells. Overall, 400 patients (45%) were alive at
the time of most recent reporting, and 187 patients were
alive with a follow-up of more than 3 years. Forty-five of
these surviving patients (11%) have relapsed. The major
cause of failure after transplantation was treatment-related
mortality. A total of 324 patients died because of treatment-
related complications and 161 patients died after relapse.
The actuarial probability of disease-free survival at 3 years
was 36%, and the relapse risk was 36% (Figs 1 and 2,
Table I).
A number of possible prognostic factors were studied by
univariate analysis, i.e. type of MDS, age, disease stage,
interval from diagnosis to transplantation and year of
transplant. The 3-year disease-free survival of patients
transplanted for primary MDS was 37%. This was not
significantly different from a DFS of 32% for patients who
had developed AML after MDS (Table I). The treatment-
related mortality was the same for both groups, but the risk
of relapse was significantly higher (P , 0´001) for the
patients transplanted after development of AML. Sixty-seven
patients were transplanted for therapy-related MDS
(n  30) or t-AML (n  37). Patients transplanted for t-
MDS/AML had a similar outcome after transplantation to
patients transplanted for primary MDS and MDS-AML
(Table I).
Age has a significant effect on outcome. Patients aged
, 20 years had a DFS of 45%, which compared favourably
with the outcome in patients transplanted between 20 and
40 years (37%) and patients older than 40 years at the time
of transplant (31%). These significantly (P , 0´001) better
results can be explained by a lower treatment-related
mortality in the younger patients. The risk of relapse was
similar for all three age categories (Table I).
The stage of disease and disease status are important
prognostic factors for outcome after transplantation. A total
of 215 patients received the transplant as primary treat-
ment, and 670 patients were transplanted after intensive
chemotherapy. The DFS of the 72 patients transplanted with
RA/RARS or the 230 patients transplanted in CR-1 were
significantly better (P , 0´001) than the DFS when the
Fig 1. Disease-free survival (DFS) of patients with myelodysplastic
syndromes transplanted with stem cells from: histocompatible
siblings (HLA-ID); genotypically non-identical relatives (FAMNID);
volunteer unrelated donors (VUD); autologous stem cells (AUTO).
Fig 2. Relapse risk of patients with myelodysplastic syndromes
transplanted with stem cells from: histocompatible siblings (HLA-
ID); genotypically non-identical relatives (FAMNID); volunteer
unrelated donors (VUD); autologous stem cells (AUTO).
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transplant was performed for more advanced stages of MDS
(Table I). The risk of relapse was only 13% for RA or RARS
and 30% for CR-1. This contrasts with the relapse risks of
43% and 42% when the transplant was performed for more
advanced MDS or after failure of chemotherapy respectively
(Table I). The survival and DFS of patients transplanted at
an early stage were significantly (P , 0´001) better than
the DFS of patients transplanted at a later phase of the
disease (Fig 3, Table I). The survival and DFS of inter-
mediate-risk and more advanced risk patients did not differ
significantly. Both the higher relapse risk and the higher
treatment-related mortality contributed to this impaired
DFS for patients transplanted at an advanced phase of the
disease (Fig 4).
The interval from diagnosis to transplant did not affect
the survival and DFS significantly, except for relapse. Several
analyses on subgroups of patients did not reveal an
advantage of transplantation within 6 or 12 months after
diagnosis (data not shown). One explanation may be that
the majority of patients (665 out of 885 patients) were
transplanted within 1 year of diagnosis.
In general, the results of allogeneic transplantation have
improved over the years (Bortin et al, 1992). For this reason,
we compared the treatment outcomes of patients trans-
planted in three periods, namely before 1989, 1989±91 and
1992±94 (Table I). The 3-year survival and DFS were better
in patients transplanted after 1989. This resulted from a
decrease in treatment-related mortality over recent years.
Multivariate analysis of prognostic variables
In view of the results from the univariate analyses (Table I),
the multivariate analysis for DFS, survival and treatment-
related mortality was restricted to the following variables:
age, stage of disease at transplant and year of transplanta-
tion. Both age and stage of disease had independent
prognostic significance for all three end-points (Table II).
Increasing age had a gradually worsening effect. Early stage
disease had a significantly improved outcome compared
Table I. Three-year actuarial probability of disease-free survival (DFS), survival, treatment-related mortality (TRM) and relapse of HLA-
identical donor transplants in MDS.
Patient categories Number DFS Survival TRM Relapse
All patients 885 36 41 43 36
Diagnosis
Primary MDS 712 37 42 43 35
MDS-AML 106 32 37 38 49
tMDS/AML 67 35 35 46 36
P-value 0´18 0´39 0´69 , 0´001
Age (years)
, 20 163 45 53 30 36
20±40 388 37 41 43 35
. 40 329 31 35 50 39
P-value 0´001 , 0´001 , 0´001 0´92
Stage at transplantation
Untreated
RA/RARS 72 55 53 37 13
RAEB(t)/MDS-AML 111 28 31 52 43
Treated
CR-1 230 44 49 37 30
No CR-1 440 32 38 45 42
P-value , 0´001 0´002 0´02 , 0´001
Early stage 302 47 50 37 26
Intermediate stage 125 29 33 49 43
Advanced stage 458 32 37 46 42
P-value , 0´001 , 0´001 0´005 , 0´001
Interval: diagnosis±transplantation
12 months 665 34 39 43 40
. 12 months 194 43 48 43 24
P-value 0´27 0´48 0´41 0´001
Year of transplant
Before 1989 156 31 35 50 39
1989±91 166 39 43 36 39
1992±94 325 40 43 42 31
P-value 0´06 0´05 0´04 0´41
Early stage, RA/RARS (untreated) or patients transplanted in CR-1; intermediate, untreated RAEB(t) or patients transplanted in CR-2;
advanced stage, remaining patients.
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with transplant for intermediate and advanced stage
disease. The year of transplant had no or only a marginal
effect on DFS and survival, whereas the treatment-related
mortality of patients transplanted before 1989 was sig-
nificantly higher than the TRM of patients transplanted
after 1989 (Table II) The relapse risk was analysed using
the variables diagnosis, stage at transplant and interval
from diagnosis to transplantation (Table III). The risk of
relapse was higher when MDS had progressed to AML, but
the risk of relapse was not higher for patients with therapy-
related MDS than for patients with primary MDS. Patients
transplanted in early disease had a significantly lower risk of
relapse than patients transplanted at more advanced stages.
Patients transplanted more than 1 year after diagnosis had
a significantly lower relapse risk, similar to the univariate
analysis (Table III).
Transplantation with voluntary unrelated donors
The DFS of the 198 patients transplanted with voluntary
unrelated donors was 25% (Fig 1). This was lower than the
DFS observed after matched-sibling transplantation despite
the younger age in this type of transplant. The TRM was
58% and the relapse risk 41% (Fig 2, Table IV). Age had a
remarkable impact on treatment outcome. The DFS was
36% when patients were younger than 20 years at the time
of transplant and 19% and 11% when patients were
between 20 and 40 years or older than 40 years respec-
tively. Treatment-related mortality was high in all age
groups, but was age dependent (Table IV).
Transplantation with genotypically non-identical related donors
The 3-year DFS of the 91 patients transplanted with stem
cells from alternative family donors was 28% (Fig 1,
Table IV). The main cause of failure was a treatment-
related mortality of 66%, higher than in any other type of
transplantation. The relapse rate of 18% was low (Fig 2,
Table IV). Age had no significant influence on treatment
outcome when genotypically non-identical family members
Fig 3. Survival and disease-free survival (DFS) of patients trans-
planted with stem cells from histocompatible siblings in early stage
(untreated RA/RARS or CR-1), intermediate stage (untreated
RAEB/RAEBt or CR-2) and advanced stage (untreated MDS-AML
or no CR-1/CR-2) disease.
Fig 4. Treatment-related mortality (TRM) and relapse risk of
patients transplanted with stem cells from histocompatible siblings,
in early stage (untreated RA/RARS or CR-1), intermediate stage
(untreated RAEB/RAEBt or CR-2) and advanced stage (untreated
MDS-AML or no CR-1/CR-2) disease.
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served as donors. Other factors, such as degree of mismatch
and stage of disease, apparently had a more important
effect.
Autologous stem cell transplantation
The 3-year DFS of the 173 patients transplanted with
autologous stem cells was 30% (Table IV, Fig 1). The
treatment-related mortality of 29% was lower than in
other forms of transplantation. The majority of autologous
transplants were performed in CR-1. The DFS of the 126
patients transplanted in CR-1 was 33%. Treatment failure
resulted mainly from a high relapse risk of 55%. Non-relapse
mortality was 25%. The DFS of patients transplanted
beyond CR-1 was 18%. Age had a borderline significant
effect on treatment outcome. The DFS was 46% when
patients were younger than 20 years at the time of
transplant. The DFS was 29% when the patients were
older than 40 years. This difference can be explained by a
higher treatment-related mortality in the older age group
(Table IV). The relapse incidence was similar for all age
groups.
DISCUSSION
Most patients with MDS are too old to be considered for
intensive treatment such as stem cell transplantation. In
patients younger than 60 years, allogeneic stem cell
transplantation has become a curative treatment option.
The EBMT reported its first analysis on a large group of
patients in 1990 (de Witte et al, 1990b). The results were
encouraging, but the follow-up was limited. Now, we
present the long-term results of more than 1000 patients
transplanted for MDS. In addition, this analysis presents
data from patients transplanted with sources of haemato-
poietic stem cells other than histocompatible sibling donors.
Young patients with RA and RARS are considered good
candidates for allogeneic BMT. Relapses are rare, provided
that the pretransplant conditioning includes a marrow
ablative regimen (Appelbaum et al, 1990). Disease-free
survival in this analysis was 55%, in accordance with other
reports (Appelbaum et al, 1990; de Witte et al, 1990b,
Mattijssen et al, 1997). The high treatment-related mortal-
ity suggests that early transplantation is indicated before
there is sensitization as a result of transfusion of blood
products, before the development of iron overload and
opportunistic infections and before transformation to more
Table II. Multivariate analysis in patients transplanted with stem cells from HLA-identical siblings.
DFS Survival TRM
Number RR 95% CI P RR 95% CI P RR 95% CI P
Age (years)
, 20 163 1´00 1´00 1´00
20±40 388 1´41 1´10±1´82 0´007 1´64 1´25±2´16 , 0´001 1´83 1´28±2´64 0´001
. 40 329 1´76 1´36±2´27 , 0´001 2´07 1´56±2´73 , 0´001 2´47 1´71±3´57 , 0´001
Stage
Early 299 1´00 1´00 1´00
Intermediate 125 1´63 1´25±2´13 0´003 1´61 1´22±2´13 , 0´001 1´54 1´11±2´15 0´01
Advanced 456 1´57 1´29±1´91 , 0´001 1´47 1´19±1´80 , 0´001 1´34 1´04±1´72 0´02
BMT year
Before 1989 156 1´00 1´00 1´00
1989±91 166 0´78 0´59±1´02 0´07 0´76 0´58±1´01 0´06 0´64 0´45±0´91 0´01
1992±94 325 0´79 0´62±1´01 0´06 0´78 0´61±1´00 0´05 0´74 0´55±0´99 0´04
After 1994 235 0´83 0´63±1´09 0´17 0´76 0´57±1´02 0´07 0´69 0´49±0´97 0´03
Early stage, RA/RARS (untreated) or patients transplanted in CR-1; intermediate stage, untreated RAEB(t) or patients transplanted in CR-2;
advanced stage, remaining patients.DFS RR, relative risk of disease-free survival: time to relapse or death; Survival RR, relative risk of survival
time to death; TRM RR, relative risk of time to death related to treatment; CI, confidence intervals.
Table III. Multivariate analysis in patients transplanted with stem
cells from HLA-identical siblings; relative risk (95% confidence
intervals)of relapse.
Relapse incidence
RR 95% CI P
Diagnosis
Primary MDS 690 1´00
MDS-AML 103 2´29 1´57±3´36 , 0´001
Therapy-related 66 1´14 0´68±1´91 0´62
Stage
Early 299 1´00
Intermediate 125 2´25 1´41±3´59 0´001
Advanced 456 2´43 1´72±3´41 , 0´001
Interval: diagnosis±BMT
12 months 665 1´00
. 12 months 194 0´62 0´42±0´91 0´01
Early stage, RA/RARS (untreated) or patients transplanted in CR-
1; intermediate stage, untreated RAEB(t) or patients transplanted in
CR-2; advanced stage, remaining patients.
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advanced stages of MDS or AML. This analysis could not
show a clear benefit of transplantation within 12 months
when an HLA-identical sibling donor was available (Table I).
This observation may be explained by the inclination of
physicians to transplant high-risk patients earlier than low-
risk patients because the multivariate analysis showed a lower
relapse risk when patients were transplanted more than
12 months after diagnosis (Table III). However, the TRM
appeared to be lower in patients transplanted within
3 months after diagnosis in an earlier multivariate analysis
by the EBMT (Runde et al, 1998). Postponement of
allogeneic stem cell transplantation may be justified in
patients with a relatively good prognosis. These patients are
characterized by an absence of profound cytopenias and an
absence of poor prognostic cytogenetic characteristics
(Greenberg et al, 1997).
An increase in the proportion of marrow blasts to more
than 5% had a negative impact on DFS after transplanta-
tion. The DFS was 55% when patients were transplanted for
RA or RARS compared with a DFS of 28% in patients with
more than 5% marrow blasts. This inferior outcome
resulted mainly from an increased risk of relapse. A recent
analysis by the EBMT of 131 MDS patients treated by HLA-
identical sibling BMT confirmed that bone marrow blast
count is the most important risk factor for increased relapse
and decreased survival (Runde et al, 1998). One of the
analyses from Seattle (Appelbaum et al, 1990) reported an
actuarial relapse risk of 45% in 30 patients transplanted
with RAEB or RAEBt.
The results of allogeneic BMT as primary therapy
appeared to be worse for patients with overt AML after
MDS than for patients transplanted at earlier stages of MDS-
AML (de Witte et al, 1990b; Sutton et al, 1996; Anderson
et al, 1997; Runde et al, 1998). Disease-free survival was
approximately 20% when patients were transplanted for
MDS-AML (de Witte et al, 1990b; Anderson et al, 1997;
Runde et al, 1998). The alternative approach is to offer
allogeneic BMT to these patients as consolidation therapy in
complete or partial remission after intensive AML-type
remission-induction chemotherapy (Armitage et al, 1981;
de Witte et al, 1990a; Fenaux et al, 1991). The 3-year DFS
was 44% for 230 patients transplanted in complete
remission after chemotherapy. Patients not in first remission
after chemotherapy responded less well and showed a 3-
year DFS of 32%. The issue as to whether patients with
MDS-AML or RAEBt should receive remission-induction
therapy before the transplant procedure is controversial.
Some patient categories may be identified that are unlikely
to enter CR after intensive chemotherapy. These patients are
characterized by a prolonged history of MDS, by hypo-
cellular marrow or by multiple chromosomal abnormalities.
In these cases, allogeneic BMT may be considered as first-
line therapy (Marmont & Tura, 1986; Anderson et al,
1997). Only large prospective studies may resolve this issue.
In the report from Seattle (Anderson et al, 1997), no
significant difference in outcome was observed between
patients treated with immediate transplantation and
patients treated after remission-induction therapy. However,
the numbers are limited, and only six of the 20 patients
treated with chemotherapy before the transplant procedure
received the transplant in CR-1 (Anderson et al, 1997).
Increasing numbers of patients with malignancies are
treated successfully with radiochemotherapy. Therefore, there
are a number of patients who present with treatment-related
MDS. In several reports, patients transplanted for t-MDS
tended to have a lower DFS than patients transplanted for
primary MDS (Longmore et al, 1990; Anderson et al, 1997).
A previous report from the EBMT (Runde et al, 1998)
showed an identical DFS, but the relapse rate was slightly
higher in the therapy-related group. This analysis and
another recent report (Ballen et al, 1997) confirm an
identical DFS and relapse risk of patients transplanted for
t-MDS to that for patients with primary MDS.
Two-thirds of the patients with MDS who may benefit
from allogeneic BMT lack a suitable family donor. The
development of efficient, worldwide registries of HLA-typed
volunteer unrelated donors (VUDs) has made allogeneic
BMT with fully or partially matched unrelated donors a
realistic alternative. Three recent analyses reported an 18±
38% DFS (Kernan et al, 1993; Anderson et al, 1996; Arnold
et al, 1998). Non-relapse mortality was higher than that of
HLA-identical related recipients. Increasing age was sig-
nificantly associated with increased risk of death from non-
relapse causes (Anderson et al, 1996; Arnold et al, 1998).
The DFS of 36% in patients younger than 20 years is very
encouraging and similar to the results obtained with
histocompatible sibling transplantation. On the other
hand, the poor outcome of the 22 patients older than
Table IV. Three-year actuarial probability of disease-free survival
(DFS), survival, treatment-related mortality (TRM) and relapse of
patients treated with voluntary unrelated donor (VUD) transplants,
genotypically non-identical related donor transplants (Fam-nonid)
in MDS/sAML and autologous transplants: the influence of age on
treatment outcome.
Patient category Number DFS Survival TRM Relapse
VUD transplants 198 25 26 58 41
, 20 years 84 36 36 45 35
20±40 years 81 19 22 65 44
. 40 years 33 11 13 73 59
P-value 0´03 0´03 0´004 0´01 0´39
Fam-nonid. transplants 91 28 31 66 18
, 20 years 36 14 23 81 27
20±40 years 32 41 41 47 22
. 40 years 23 27 27 71 5
P-value 0´14 0´44 0´10 0´67
Autologous transplants 173 30 32 29 58
CR-1 126 33 38 25 55
No CR-1 47 18 14 51 64
P-value 12 0´06 0´01 0´07 0´32
, 20 years* 48 46 58 17 44
20±40 years* 66 36 41 15 58
. 40 years* 29 29 39 51
P-value 0´08 0´05 0´22 0´27
*Only patients in first complete remission.
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40 years transplanted with stem cells from unrelated
donors indicates that these patients should not be trans-
planted unless substantial improvements in the technology
have been achieved.
Autologous stem cell transplantation (ASCT) may be an
alternative option for patients ineligible for allografting. A
primary requisite for ASCT is a complete remission with
sufficient numbers of stem cells. Multidrug chemotherapy,
such as that applied to induce CR in primary AML, is
effective in MDS with CR rates varying from 15% to 64%
(Mertelsmann et al, 1980; Armitage et al, 1981; Preisler
et al, 1986; Michels et al, 1989; de Witte et al, 1990a,
O'Donnell et al, 1995; Parker et al, 1997). The experience
with ASCT in patients with MDS is limited (Geller et al,
1988; Laporte et al, 1993). A recent report from the EBMT
showed a DFS of 28% for 55 patients with MDS and 51% for
a matched group transplanted for de novo AML (de Witte
et al, 1997). In this report, the 3-year DFS of the 126
patients transplanted in CR-1 was 33%, and the actuarial
relapse rate was 55%. Patients younger than 40 years had a
better DFS than patients aged $ 40 years. This difference
could be explained by the higher non-relapse mortality in
the older age group.
Myelodysplastic syndromes are clonal stem cell disorders.
This may raise concern about the presence of sufficient
numbers of residual normal stem cells to perform ASCT.
Chemotherapy induces cytogenetically normal CRs in the
majority of patients (de Witte et al, 1995). In addition, the
peripheral stem cell harvests of three patients with MDS
appeared to be polyclonal, when assessed by polymerase
chain reaction (PCR) techniques based on X-chromosome
inactivation patterns (Delforge et al, 1995). Preliminary
data indicate that repopulation after transplantation with
mobilized peripheral stem cells was much faster than
autologous bone marrow transplantation (Carella et al,
1996; Demuynck et al, 1996).
Both allogeneic and autologous stem cell transplantation
have emerged as treatment options for patients with myelo-
dysplastic syndromes. The DFS of the patients transplanted
with matched sibling stem cells was superior to that of
patients transplanted with other sources of stem cells
(Fig 1). Therefore, transplantation with an HLA-identical
sibling donor is the preferred treatment option. Young
patients, patients transplanted at an early stage of the
disease and those transplanted more recently benefited more
clearly from an HLA-identical sibling transplantation than
the other patients. Patients without an HLA-identical sibling
donor may be treated with either autologous stem cell
transplantation or an alternative donor transplantation.
Autologous stem cell transplantation requires a CR that has
been maintained for at least several months. Multivariate
analysis cannot yet identify which patient should be treated
with which treatment modality. Careful interpretation of the
data from this analysis indicates that young patients
(, 20 years) may be treated with an unrelated donor
transplantation. This approach results in a 3-year DFS of
36% (Table IV). Patients older than 40 years, and probably
also patients between 20 and 40 years, will benefit most
from an autologous stem cell transplantation. Only data
from large numbers of patients with sufficient follow-up
data may allow a multivariate analysis, which may answer
these questions.
PARTICIPATING EBMT TRANSPLANT CENTRES,
PHYSICIAN (NUMBER OF CASES)
University Hospital, Nijmegen, T. de Witte (57); University
Hospital, Leiden, R. Willemze/J. Vossen (52); Ospedale San
Martino, Genova, A. Bacigalupo (44); University of degli
Studi La Sapienza, Rome, W. Arcese (34); Rigshospitalet,
Copenhagen, N. Jacobsen (32); Helsinki University Central
Hospital, Helsinki, T. Ruutu (31); Hopital St. Louis, Paris, A.
Devergie (28); Karolinska Institute, Huddinge, G. Gahrton
(28); Kantonsspital, Basel, A. Gratwohl (27); AZR/DDHK,
Rotterdam, J. Cornelissen (26); Hopital Claude Hurez, Lille,
F. Bauters (25); University Hospital Gasthuisberg, Leuven,
M. Boogaerts (24); Hopital Henri-Mondor, Creteil, M. Kuentz
(23); University Hospital, Essen, V. Runde (22); Klinikum
Grosshadern, Munich, H. J. Kolb (22); Charing Cross±
Hammersmith Hospital, London, D. Samson/J. Apperley
(22); University of Ulm, Ulm, D. Bunjes (21); Hopital Saint
Antoine, Paris, N. Gorin (21); Cliniques Universitaires St
Luc, Brussels, A. Ferrant (21); Hopital Jean Minjoz,
Besancon, J.Y. Cahn (20); Royal Free Hospital, London, H.
Prentice (19); Hospital University of `MarqueÂs de Valdecilla',
Santander, A. Iriondo (19); Medical School of Hannover,
Hannover, B. Hertenstein (18); Heinrich-Heine-UniversitaÈt,
DuÈ sseldorf, W. Schneider (17); University Hospital, Utrecht,
L. Verdonck (16); Pitie-Salpetriere, Paris, V. Leblond (16);
Hopital du Haut Leveque, Pessac, J. Reiffers (16); Policlinico
San Matteo (Paediatric), Pavia, F. Locatelli (15); Institute of
Haematology and Blood Transfusion, Praha, A. Vitek (15);
CHU Sart-Tilman, Liege, Y. Beguin (15); Policlinico San
Matteo (Adult), Pavia, E. Alessandrino (14); Great Ormond
Street Hospital, London, P. Veys (12); Clinica Medica
Universita, Torino, M. Aglietta (11); University Hospital,
Uppsala, B. Simonsson (11); University Hospital (Paedia-
trics), TuÈ bingen, D. Niethammer (11); Hopital E. Herriot,
Lyon, M. Michallet (11); Hospital Clinic, Barcelona, E.
Carreras (10); King Faisal Specialist Hospital, Riyadh, P.
Ernst (10); Hospital Universitario La Fe, Valencia, M. Sanz
(10); University Hospital (Adults), Tubingen, H. Einsele (9);
Hopital Hotel Dieu, Paris, B. Rio (8); Royal Infirmary,
Glasgow, I. Franklin (8); Ospedale Civile, Pescara, G.
Torlontano (8); Hotel Dieu, Nantes, J. Harousseau (8);
Hadassah University Hospital, Jerusalem, S. Slavin (8); Hop.
Cantonal Universitaire, Geneva, B. Chapuis (8); Pesaro
Hospital, Pesaro, G. Lucarelli (8); University Hospital VUB,
Brussels, R. Schots (8); Institut Gustave Roussy, Villejuif, O.
Hartmann (8); Hospital San Orsola, Bologna, S. Tura (7);
Hopital Caen, Caen, X. Troussard (7); Ospedale Maggiore die
Milano, Milano, G. Lambertenghi-Deliliers (7); Ospedale San
Gerardo (Paediatrics), Monza, C. Uderzo (7); Heartlands
Hospital, Birmingham, D. Milligan (7); Ospedale di Careggi,
Firenze, A. Bosi (7); A.Z. St. Jan, Brugge, D. Selleslag (7);
Universitatskrankenhaus Eppendorf, Hamburg, H. J.
Schmoll (7); Evangelismos Hospital, Athens, A. Skandalis
(7); K. Marcinkowski University (Haematology), Poznan, J.
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Hansz (7); Hospital Universitario `Virgen del Rocio', Sevilla,
J. Rodriguez Fernandez (7); University Hospital, Zurich, J.
Gmur (6); Rikshospitalet, Oslo, S. Evensen (6); Hopital de
Nancy, Nancy, F. Witz (6); Hospital Santa Creu i Sant Paul,
Barcelona, S. Brunet (6); Hopital A. Michallon, Grenoble, L.
Molina (6); AZM, Maastricht, H. Schouten (6); University of
Cambridge, Cambridge, R. Marcus (6); Klinik fur KMT,
Hamatologie und Onkologie, Idar-Oberstein, A. Fauser (6);
Centre Henry Becquerel, Rouen, H. Tilly (6); Hopital Necker-
Enfants Malades, Paris, A. Bezyn (5); Royal Mardsden
Hospital, Sutton Surrey, R. Powles (5); University of Turku
Central Hospital, Turku, K. Remes (5); Inst. Paoli I.
Calmettes, Marseille, D. Blaise (5); Hopital Nord, St. Etienne,
J. Stephan (5); Christian-Albrechts-University, Kiel, N.
Schmitz (5); Centre Jean Perrin, Clermont-Ferrand, R.
Plagne (5); Institute G. Gaslini, Genova, G. Dini (5);
University Hospital Centre-Rebro, Zagreb, B. Labar (5);
Royal Manchester Children's Hospital, Pendlebury, A. Will
(5); The George Papanicolaou General Hospital, Thessalo-
niki, A. Fassas (5); Hopital de Purpan, Toulouse, M. Attal
(5); Hopital de Hautepierre, Strasbourg, B. Lioure (5); S.
Bortolo Hospital, Vicenza, F. Rodeghiero (5); Hopital
Debrousse, Lyon, G. Souillet (5); ChariteÂ-Virchow Klinikum,
Berlin, R. Arnold (5); Kinderpoliklinik UniversitaÈt of
MuÈ nchen, MuÈ nchen, C. Bender-GoÈtze (5); University College
Hospital, London, A. Goldstone (4); University of Vienna,
Vienna, H. Greinix (4); Hopital Cochin, Paris, F. Dreyfus (4);
University Hospital of Lund, Lund, A. Bekassy (4); Centro
Leucemie Infantili, Padova, C. Messina (4); Centor Porto,
Porto, F. Campilho (4); Inst. Portugues Oncologia, Lisboa, M.
Abecasis (4); Bristol Hospital for Sick Children, Bristol, J.
Cornish (4); R G Vall Hebron, Barcelona, A. Julia (4);
Ospedale `Bianchi-Melacrino-Morelli', Reggio Calabria, P.
Iacopino (4); University Hospital, Udine, M. Baccarani (4);
Nottingham City Hospital, Nottingham, N. Russell (4);
King's Healthcare NHS Trust, London, G. Mufti (4); St
James Hospital Trinity College, Dublin, S. McCann (3); San
Camillo Hospital, Rome, A. De Laurenzi (3); Spedali Civile,
Brescia, T. Izzi (3); Sahlgrenska University Hospital/East,
GoÈteborg, A. Fasth (3); Ospedale di Niguarda, Milano, R.
Cairoli (3); Royal Liverpool University Hospital, Liverpool, R.
Clarke (3); National Institute of Haematology, Budapest, E.
Kelemen (3); Hopital Erasme, Brussels, W. Feremans (3);
University Hospital, Bratislava, M. Mistrik (3); University of
Verona, Verona, F. Benedetti (3); CHRU, Angers, M. Boasson
(3); Heinrich-Heine-University (Paediatrics), DuÈ sseldorf, S.
Burdach (3); Hospital Infantil La Fe, Valencia, V. Castel (3);
Hopital d'Enfants CHU de Dijon, Dijon, D. Caillot (3); Perth
Royal Infirmary, Perth, R. Herrmann (3); Hospital Clinico,
Salamanca, D. Caballero (3); Hopital Robert Debre, Paris, E.
Vilmer (3); University Hospital, Innsbruck, D. Niederwieser
(2); Royal Victoria Infirmary, Newcastle, S. Proctor (2);
University of Ulm (Paediatrics), Ulm, W. Friedrich (2);
Hopital d'Enfants de la Timone, Marseille, C. Coze (2);
Universita Cattolica S. Cuore, Rome, G. Leone (2); Clinica
Paediatrica, Trieste (2); Hospital Mat Infantil Vall d'Hebron,
Barcelona, J. Ortega (2); Poole Hospital, Dorset, D. Spence
(2); Hospital Aranzazu, San Sebastian, R. Lasa Isasti (2);
Klinikum NuÈ rnberg, NuÈ rnberg, H. Wandt (2); Ospedale
Bergamo, Bergamo, T. Barbui (2); Hopitaux de Brabois
(Paediatrics), Nancy, P. Bordigoni (2); Sahlgrenska Univer-
sity Hospital (Haematology), GoÈteborg, J. Carneskog (2);
Hospital Son Dureta, Palma de Mallorca, J. Besalduch (2); St
LaÂszloÂ Hospital, Budapest, T. Masszi (2); Antartida Hospital
Privado, Buenos Aires, L. Feldman (2); University of Jena,
Jena, F. Zintl (2); Tel Aviv University, Tel Hashomer, I. Ben-
Bassat (2); Schneider Children's Medical Centre of Israel,
Petach-Tikva, I. Yaniv (2); Universita Tor Vergata/St
Eugenio Hospital, Rome, S. Amadori (2); Clinica Corachan,
Barcelona, A. Granena (2); Hospital of Manchester, Man-
chester, G. Morgensterne (2); Policlinico Monteluce, Per-
ugia, M. Martelli (2); Universita di Palermo, Palermo, A.
Cajozzo (2); Institut Jules Bordet, Brussels, P. Stryckmans
(2); Children's Hospital, Helsinki, U. Pihkala (1); Hospital
Reina Sofia, Cordoba, A. Torres Gomez (1); AMC/Emma
Kinderziekenhuis, Amsterdam, H. vd Berg (1); The Oxford
Radcliffe Hospital, Oxford, T. Littlewood (1); Hopital La
Miletrie, Poitiers, F. Guilhot (1); The London Clinic, London,
D. GueÂret-Wardle (1); Hospital Clinico Universitario, Valen-
cia, J. Garcia-Conde (1); Ospedale Regina Margherita,
Torino, R. Miniero (1); HCI International Medical Centre,
Clydebank, D. Spence (1); Queen Elizabeth Medical Centre,
Birmingham, J. Murray (1); UCT Medical School, Cape
Town, N. Novitzky (1); St Anna Kinderspital, Vienna, H.
Gadner (1); Polish Academy of Sciences, Wroclaw, A. Lange
(1); St George's Hospital, London, J. Marsh (1); Hopital
Huguenin, St. Cloud, X. Janvier (1); Klinikum Benjamin
Franklin, Berlin, W. Knauf (1); Ibni Sina Hospital, Ankara,
H. Koc (1); Karolinska Hospital, Stockholm, M. BjoÈrkholm
(1); Children University Hospital, Brussels, C. Devalck (1);
The New Children's Hospital, Sydney, P. Shaw (1); Marmara
University of Hastanesi, Istanbul, T. Akoglu (1); Charles
University Hospital, Pilsen, V. Koza (1); Clinca Puerta de
Hierro, Madrid, M. Fernandez (1); Hospital Nino Jesus of
Madrid, Madrid, L. Madero (1); Orebro Medical Centre
Hospital, Orebro, U. Tidefelt (1); University Hospital.
LinkoÈping, G. Juliusson (1); Stadt Kliniken Oldenburg,
Oldenburg, B. Metzner (1); Hospital Duran i Reymais,
Barcelona, A. Granena (1); Istanbul Medical School,
Istanbul, Y. Tangun (1); Our Lady's Hospital for Sick
Children, Dublin, A. O'Meara (1); The Children's Hospital,
Sheffield, E. Vandenberghe (1); University Hospital, Hom-
burg, L. Trumper (1); Ospedale di Torrette, Ancona, P. Leoni
(1); Ospedale `San Francesco', Nuoro, A. Gabbas (1); Hopital
Saint Louis (Adults), Paris, C. Gisselbrecht (1); University of
Erlangen-Nuremberg, Erlangen, M. Gramatzki (1); Ospedale
Regionale Microcitimie, Cagliari, A. Cao (1); Riyadh Armed
Forces Hospital, Riyadh, M. Aldouri (1); Derriford Hospital,
Plymouth, M. Hamon (1).
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